The Role of FGF19 and MALRD1 in Enterohepatic Bile Acid Signaling

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 Feb 4

PMID 35116006

Authors

Linda X Wang

Mark R Frey

Rohit Kohli

Affiliations

Soon will be listed here.

Abstract

Bile acids are the catabolic end products of cholesterol metabolism that are best known for their role in the digestion of lipids. In the last two decades, extensive investigation has shown bile acids to be important signaling molecules in metabolic processes throughout the body. Bile acids are ligands that can bind to several receptors, including the nuclear receptor farnesoid X receptor (FXR) in ileal enterocytes. FXR activation induces the expression of fibroblast growth factor (FGF) 15/19, a hormone that can modulate bile acid levels, repress gluconeogenesis and lipogenesis, and promote glycogen synthesis. Recent studies have described a novel intestinal protein, MAM and LDL Receptor Class A Domain containing 1 (MALRD1) that positively affects FGF15/19 levels. This signaling pathway presents an exciting target for treating metabolic disease and bile acid-related disorders.

Citing Articles

Identification of chikusetsusaponin IVa as a novel lysine-specific demethylase 1 inhibitor that ameliorates high fat diet-induced MASLD in mice.

Liu Y, Luo R, Liu A, Wang J, Hu N, Li W Acta Pharmacol Sin. 2024; 46(3):632-652.

PMID: 39567752 PMC: 11845606. DOI: 10.1038/s41401-024-01412-7.

Clinical value of fibroblast growth factor 19 in predicting gastrointestinal dysfunction in patients with sepsis.

Guan L, Wang F, Chen J, Xu Y, Zhang W, Zhu J Front Nutr. 2024; 11:1442203.

PMID: 39296513 PMC: 11408290. DOI: 10.3389/fnut.2024.1442203.

Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment.

Zhang R, Yan Z, Zhong H, Luo R, Liu W, Xiong S Hepatol Commun. 2024; 8(7).

PMID: 38967596 PMC: 11227362. DOI: 10.1097/HC9.0000000000000484.

Novel approaches in IBD therapy: targeting the gut microbiota-bile acid axis.

Pan Y, Zhang H, Li M, He T, Guo S, Zhu L Gut Microbes. 2024; 16(1):2356284.

PMID: 38769683 PMC: 11110704. DOI: 10.1080/19490976.2024.2356284.

Dysregulated intestinal nutrient absorption in obesity is associated with epigenomic alterations in epithelia.

Badurdeen D, Li Z, Lee J, Ma T, Bhagwate A, Latanich R bioRxiv. 2024; .

PMID: 38766131 PMC: 11100618. DOI: 10.1101/2024.05.06.591758.

References

Reue K, Lee J, Vergnes L . Diet1 is a regulator of fibroblast growth factor 15/19-dependent bile acid synthesis. Dig Dis. 2015; 33(3):307-13. PMC: 4809532. DOI: 10.1159/000371649. View

Kullak-Ublick G, Stieger B, Meier P . Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology. 2003; 126(1):322-42. DOI: 10.1053/j.gastro.2003.06.005. View

Claudel T, Staels B, Kuipers F . The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol. 2005; 25(10):2020-30. DOI: 10.1161/01.ATV.0000178994.21828.a7. View

Repana D, Ross P . Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma. Diseases. 2017; 3(4):294-305. PMC: 5548263. DOI: 10.3390/diseases3040294. View

Tang M, Su J, Xu T, Wang X, Zhang D, Wang X . Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients. Diabetol Metab Syndr. 2019; 11:79. PMC: 6760053. DOI: 10.1186/s13098-019-0475-1. View

Gerhard G, Styer A, Wood G, Roesch S, Petrick A, Gabrielsen J . A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care. 2013; 36(7):1859-64. PMC: 3687273. DOI: 10.2337/dc12-2255. View

Duboc H, Rajca S, Rainteau D, Benarous D, Maubert M, Quervain E . Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2012; 62(4):531-9. DOI: 10.1136/gutjnl-2012-302578. View

Wang W, Wu Z, Dai Z, Yang Y, Wang J, Wu G . Glycine metabolism in animals and humans: implications for nutrition and health. Amino Acids. 2013; 45(3):463-77. DOI: 10.1007/s00726-013-1493-1. View

Chiang J . Bile acid metabolism and signaling. Compr Physiol. 2013; 3(3):1191-212. PMC: 4422175. DOI: 10.1002/cphy.c120023. View

10.

Schreuder T, Marsman H, Lenicek M, van Werven J, Nederveen A, Jansen P . The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol. 2010; 298(3):G440-5. DOI: 10.1152/ajpgi.00322.2009. View

11.

Dawson P . Role of the intestinal bile acid transporters in bile acid and drug disposition. Handb Exp Pharmacol. 2010; (201):169-203. PMC: 3249407. DOI: 10.1007/978-3-642-14541-4_4. View

12.

Hollman D, Milona A, van Erpecum K, van Mil S . Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. Biochim Biophys Acta. 2012; 1821(11):1443-52. DOI: 10.1016/j.bbalip.2012.07.004. View

13.

Norman A . Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology. 2006; 147(12):5542-8. DOI: 10.1210/en.2006-0946. View

14.

Goetz R, Mohammadi M . Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol. 2013; 14(3):166-80. PMC: 3695728. DOI: 10.1038/nrm3528. View

15.

Sayin S, Wahlstrom A, Felin J, Jantti S, Marschall H, Bamberg K . Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013; 17(2):225-35. DOI: 10.1016/j.cmet.2013.01.003. View

16.

Rao A, Haywood J, Craddock A, Belinsky M, Kruh G, Dawson P . The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis. Proc Natl Acad Sci U S A. 2008; 105(10):3891-6. PMC: 2268840. DOI: 10.1073/pnas.0712328105. View

17.

Frankenberg T, Rao A, Chen F, Haywood J, Shneider B, Dawson P . Regulation of the mouse organic solute transporter alpha-beta, Ostalpha-Ostbeta, by bile acids. Am J Physiol Gastrointest Liver Physiol. 2005; 290(5):G912-22. DOI: 10.1152/ajpgi.00479.2005. View

18.

Phan J, Pesaran T, Davis R, Reue K . The Diet1 locus confers protection against hypercholesterolemia through enhanced bile acid metabolism. J Biol Chem. 2001; 277(1):469-77. DOI: 10.1074/jbc.M107107200. View

19.

Younossi Z, Ratziu V, Loomba R, Rinella M, Anstee Q, Goodman Z . Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019; 394(10215):2184-2196. DOI: 10.1016/S0140-6736(19)33041-7. View

20.

Peng D, Wang J, Zhang R, Jiang F, Tang S, Chen M . Common variants in or near ZNRF1, COLEC12, SCYL1BP1 and API5 are associated with diabetic retinopathy in Chinese patients with type 2 diabetes. Diabetologia. 2015; 58(6):1231-8. DOI: 10.1007/s00125-015-3569-9. View